Opus Genetics, Inc. Common Stock

IRDNASDAQ • USD
5.47 USD
↗ 0.13 (2.43%)AT CLOSE (11:59 AM EDT)
5.46
↘ 0.13 (2.36%)
POST MARKET (AS OF 05:27 PM EDT)
Post Market
AS OF 05:27 PM EDT
5.46
↘ 0.13 (2.36%)
🟢Market: OPEN
Open?$5.28
High?$5.57
Low?$5.28
Prev. Close?$5.34
Volume?570.3K
Avg. Volume?783.7K
VWAP?$5.43
Rel. Volume?0.73x
Bid / Ask
Bid?$4.74 × 100
Ask?$6.27 × 100
Spread?$1.53
Midpoint?$5.51
Valuation & Ratios
Market Cap?381.3M
Shares Out?71.1M
Float?44.7M
Float %?74.7%
P/E Ratio?N/A
P/B Ratio?24.84
EPS?-$0.69
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.43Strong
Quick Ratio?6.43Strong
Cash Ratio?5.80Strong
Debt/Equity?0.07Low
ValuationRICHLY VALUED
Score
50/100
P/E?
N/A▾
P/B?
24.84HIGH▾
P/S?
26.86HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
-8.8CHEAP▾
EV/Sales?
23.76HIGH▾
Returns & Efficiency
ROE?
-323.1%WEAK▾
ROA?
-98.7%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$337.3M
Related Companies
MGTXNTLAMGXBMRNTNYAOCGNBNTCABEOTSHASLDBRCKTKRYSQURENGNEDSGNSRPTCRSPLXEORGNXPRME
News
Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Employees
28
Market Cap
381.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.opusgtx.com
Listed
2020-11-06
Address
8 DAVIS DRIVE
DURHAM, NC 27713
Phone: 248-681-9815
MarketsMoversWatchlist